A clinical study by Juul Labs was presented at the Society for Research on Nicotine & Tobacco 2019 Annual Meeting found that vapor products are a good alternative to regular cigarettes.
The study followed the short-term biomarkers of exposure (BOE) of in 90 adults who either used their usual brand of cigarettes, JUUL vapor products or abstained from cigarettes for five days.
The short-term biomarkers identified are carcinogens related to tobacco-related cancers.
All 90 subjects abstained for 12 hours before urine samples were taken for the baseline samples. For those who abstained, all eight non-nicotine BOE’s were reduced by 85.3 percent total and the JUUL users had a reduction of 85 percent.
Those who continued to smoke their normal brand of cigarettes saw their BOEs increase by a total of 14.4 percent. Juul is not allowed by FDA regulations to claim their products are less harmful than cigarettes.
"We are very pleased to share these findings with fellow researchers at SRNT 2019, which continue to demonstrate the potential positive impact of vapor products," said Kevin Burns, chief executive officer at Juul Labs. "The equivalent reductions in these specific cigarette-related biomarkers across the groups who abstained from smoking and those who used JUUL products reaffirms the role vapor products can have for the adult smoker. Although addictive, nicotine is not directly responsible for the cancers that are commonly associated with cigarette use; rather it is the harmful constituents that are present in combustible smoke. The more that can be done to eliminate cigarettes, the greater the impact will be on the public health. We are committed to conducting rigorous, scientific research as we contribute to the ongoing dialogue regarding vapor products and look forward to sharing additional research with the medical, scientific, and public health communities."
